Avantor, Inc. (AVTR)
| Market Cap | 5.19B -40.8% |
| Revenue (ttm) | 6.55B -2.0% |
| Net Income | -551.40M |
| EPS | -0.81 |
| Shares Out | 682.76M |
| PE Ratio | n/a |
| Forward PE | 9.32 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,911,140 |
| Open | 7.66 |
| Previous Close | 7.62 |
| Day's Range | 7.58 - 7.76 |
| 52-Week Range | 7.27 - 15.93 |
| Beta | 0.93 |
| Analysts | Hold |
| Price Target | 9.86 (+29.74%) |
| Earnings Date | Apr 29, 2026 |
About AVTR
Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education an... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for AVTR stock is "Hold." The 12-month stock price target is $9.86, which is an increase of 29.74% from the latest price.
News
Avantor® Announces Gerard (Jerry) Porreca as Executive Vice President, Quality and Regulatory
RADNOR, Pa., May 19, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology indu...
Avantor resumed with a Sector Perform at RBC Capital
RBC Capital resumed coverage of Avantor (AVTR) with a Sector Perform rating and $9 price target The target reflects a constructive view of the management turnaround story balanced against the…
Avantor Transcript: AGM 2026
The meeting confirmed a quorum and approved all proposals, including director elections, executive compensation, annual say-on-pay votes, and auditor ratification. No questions were raised during the Q&A session.
Avantor price target lowered to $8 from $8.50 at Evercore ISI
Evercore ISI lowered the firm’s price target on Avantor (AVTR) to $8 from $8.50 and keeps an In Line rating on the shares.
Avantor price target lowered to $8 from $10 at Stifel
Stifel lowered the firm’s price target on Avantor (AVTR) to $8 from $10 and keeps a Hold rating on the shares.
Avantor price target lowered to $9 from $11 at Citi
Citi lowered the firm’s price target on Avantor (AVTR) to $9 from $11 and keeps a Neutral rating on the shares.
Avantor Earnings Call Transcript: Q1 2026
Q1 2026 results exceeded expectations with stabilization in VWR and strong BMP order trends. Guidance for the year is reaffirmed despite inflationary headwinds, with organic revenue growth expected in the second half as Revival initiatives drive operational improvements.
Avantor Earnings release: Q1 2026
Avantor released its Q1 2026 earnings on April 29, 2026, summarizing the period's financial results.
Avantor Slides: Q1 2026
Avantor has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 29, 2026.
Avantor Quarterly report: Q1 2026
Avantor has published its Q1 2026 quarterly earnings report on April 29, 2026.
Avantor reports Q1 adjusted EPS 17c, consensus 16c
Reports Q1 revenue $1.58B, consensus $1.54B. “First quarter results exceeded our expectations due to improved execution in Bioscience and Medtech Products, and we saw stabilization in VWR,” said Emman...
Avantor backs FY26 adjusted EPS view 77c-83c, consensus 79c
Backs FY26 free cash flow view $500M-$550M. The company said, “Avantor (AVTR) reaffirmed the fiscal 2026 financial guidance it provided during its fourth quarter 2025 earnings call on February 11,…
Avantor® Reports First Quarter 2026 Results
Net sales of $1,581 million Net income of $43 million; Adjusted EBITDA of $219 million Diluted GAAP EPS of $0.06; adjusted EPS of $0.17 Operating cash flow of $59 million; free cash flow of $25 millio...
Avantor appoints Ludovic Brellier Chief Transformation Officer
Avantor (AVTR) announced that Ludovic Brellier will join the company as executive VP, Bioscience & Medtech Products & Chief Transformation Officer on May 1. Brellier will be responsible for growing…
Avantor® Announces Ludovic Brellier as Executive Vice President, Bioscience & Medtech Products (BMP) & Chief Transformation Officer
RADNOR, Pa., April 23, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology in...
Avantor unifies Masterflex portfolio to include fluid handling
Avantor (AVTR) announced the expansion of its Masterflex brand across its fluid handling portfolio, bringing together standard, configurable, and engineered-to-order peristaltic pumps, single-use asse...
Avantor® Unifies Masterflex® Portfolio to Streamline Fluid Management from R&D to Bioprocess Manufacturing
Portfolio now includes standard, configurable, and engineered-to-order peristaltic pumps, single-use assemblies, and systems for R&D through high-volume manufacturing Company to attend INTERPHEX 2026 ...
Avantor price target lowered to $7 from $8.50 at Barclays
Barclays lowered the firm’s price target on Avantor (AVTR) to $7 from $8.50 and keeps an Underweight rating on the shares. The firm adjusted targets in the life science and…
Avantor adds advanced microbial, stability testing at St. Louis site
Avantor (AVTR) announced the expansion of its North American quality control capabilities with the addition of advanced microbial and stability testing at its St. Louis manufacturing site. The enhance...
Avantor® Enhances U.S. Biomanufacturing Infrastructure with Expanded Stability and Microbial Testing Facility
St. Louis site strengthens integrated support for biopharma manufacturing RADNOR, Pa., April 13, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products...
Avantor price target lowered to $8.50 from $10 at Evercore ISI
Evercore ISI lowered the firm’s price target on Avantor (AVTR) to $8.50 from $10 and keeps an In Line rating on the shares as part of the firm’s medical technology…
Avantor® to Report First Quarter 2026 Earnings on Wednesday, April 29, 2026
RADNOR, Pa., April 3, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology ind...
Avantor says CFO R. Brent Jones to leave company on, before June 24
Avantor (AVTR) announced that Executive Vice President and CFO, R. Brent Jones, will leave the company on or before June 24. Avantor has initiated a search to identify the company’s…
Avantor® Announces CFO Transition
RADNOR, Pa., April 1, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology ind...
Avantor Proxy statement: Proxy filing
Avantor filed a proxy statement on March 27, 2026, providing details for shareholder voting and corporate governance matters.